about
Regression to the mean and predictors of MRI disease activity in RRMS placebo cohorts--is there a place for baseline-to-treatment studies in MS?Increased perfusion in normal appearing white matter in high inflammatory multiple sclerosis patients.Reliability of cortical lesion detection on double inversion recovery MRI applying the MAGNIMS-Criteria in multiple sclerosis patients within a 16-months period.Novel multiple sclerosis susceptibility loci implicated in epigenetic regulationSuccessful Replication of GWAS Hits for Multiple Sclerosis in 10,000 Germans Using the Exome Array.A multiple sclerosis-associated variant of CBLB links genetic risk with type I IFN function.Maraviroc as possible treatment for PML-IRIS in natalizumab-treated patients with MS.Correction: Increased Perfusion in Normal Appearing White Matter in High Inflammatory Multiple Sclerosis Patients.Switch to efavirenz in a protease inhibitor-containing regimen.Novel treatment of ovarian cancer cell lines with Imatinib mesylate combined with Paclitaxel and Carboplatin leads to receptor-mediated antiproliferative effects.Distinct functionality of neutrophils in multiple sclerosis and neuromyelitis optica.Boswellic acids reduce Th17 differentiation via blockade of IL-1β-mediated IRAK1 signaling.A standardised frankincense extract reduces disease activity in relapsing-remitting multiple sclerosis (the SABA phase IIa trial).T1 Recovery Is Predominantly Found in Black Holes and Is Associated with Clinical Improvement in Patients with Multiple Sclerosis.[Stem cell transplantation for multiple sclerosis. Hamburg experiences and state of international research].Development of Cortical Lesion Volumes on Double Inversion Recovery MRI in Patients With Relapse-Onset Multiple SclerosisA case of CLIPPERS syndrome responsive to tocilizumabSevere meningo-/encephalitis after daclizumab therapy for multiple sclerosisIs multiple sclerosis progression associated with the HLA-DR15 haplotype?Lipid Mediator Profiles Predict Response to Therapy with an Oral Frankincense Extract in Relapsing-Remitting Multiple Sclerosis
P50
Q26998513-4A1E5D9B-C2F7-454F-89E0-CBCEDB053965Q35182294-8A05FA1D-F679-460C-8B54-E408176DB327Q36290239-56165646-2757-464F-8BF5-769D52B78639Q37056269-154CDF40-D44F-456E-916D-7C34146B523BQ41189386-6A833B76-9767-4014-9490-E062CA9CB52EQ41724544-B2BA617F-116C-4E3E-8DFC-52587EE64B7BQ42144320-839BE3D6-4D87-4A27-9E67-4DA46DE61456Q42735691-61D1FC30-A8E5-40BB-9E25-E53EDEAE4D93Q43759296-F76A33D0-1965-4F65-89A4-97A63898F5C0Q46605996-B5D63546-8DBE-444B-B5C0-92FB31C8AC11Q46643220-184725B1-AE9F-48D0-A484-446C63ED8FEFQ46940257-55DD435F-8F52-41F6-B151-05BF7122AD9DQ47911728-A127D6FC-ADBB-426F-A478-1C49FC0211FAQ48088068-B88408C9-ED22-422A-9748-004D3EB6B624Q52944830-B960A63E-B472-4C6E-9DC7-0F9836FB823BQ64110821-8E4DAD61-F43F-4F2E-A740-25023287AC58Q64253920-EDBBE6E8-02C6-4CD1-B08C-C4D031FFF254Q91108665-BAB1EB54-93F9-4D10-897E-2D9C18F72BD7Q91994956-C44F617B-E84B-44E1-8BD0-659AF9B6CE74Q96022717-18CAED2C-EC67-407E-B946-503E71225365
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Klarissa Stürner
@ast
Klarissa Stürner
@en
Klarissa Stürner
@es
Klarissa Stürner
@nl
Klarissa Stürner
@sl
type
label
Klarissa Stürner
@ast
Klarissa Stürner
@en
Klarissa Stürner
@es
Klarissa Stürner
@nl
Klarissa Stürner
@sl
altLabel
Klarissa Hanja Stürner
@en
prefLabel
Klarissa Stürner
@ast
Klarissa Stürner
@en
Klarissa Stürner
@es
Klarissa Stürner
@nl
Klarissa Stürner
@sl
P106
P21
P31
P496
0000-0003-2199-3315